Buffalo Business & Estate Services Ltd. Makes New $11.35 Million Investment in Eli Lilly and Company $LLY

Buffalo Business & Estate Services Ltd. acquired a new position in shares of Eli Lilly and Company (NYSE:LLY) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 10,564 shares of the company’s stock, valued at approximately $11,353,000. Eli Lilly and Company comprises about 1.6% of Buffalo Business & Estate Services Ltd.’s portfolio, making the stock its 11th biggest holding.

Other hedge funds have also recently bought and sold shares of the company. Capital Research Global Investors boosted its holdings in shares of Eli Lilly and Company by 20.9% in the 3rd quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock worth $19,141,787,000 after buying an additional 4,332,008 shares during the last quarter. Amundi boosted its holdings in shares of Eli Lilly and Company by 27.1% in the 3rd quarter. Amundi now owns 4,525,902 shares of the company’s stock worth $3,823,977,000 after buying an additional 964,675 shares during the last quarter. Victory Capital Management Inc. boosted its holdings in shares of Eli Lilly and Company by 47.6% in the 3rd quarter. Victory Capital Management Inc. now owns 2,309,006 shares of the company’s stock worth $1,761,772,000 after buying an additional 744,868 shares during the last quarter. Danske Bank A S purchased a new position in shares of Eli Lilly and Company in the 3rd quarter worth about $512,022,000. Finally, Capital International Investors boosted its holdings in shares of Eli Lilly and Company by 6.1% in the 3rd quarter. Capital International Investors now owns 10,001,509 shares of the company’s stock worth $7,628,447,000 after buying an additional 579,381 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. Loop Capital set a $1,200.00 price objective on shares of Eli Lilly and Company in a report on Tuesday, February 10th. Wall Street Zen downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a report on Monday. Guggenheim dropped their price objective on shares of Eli Lilly and Company from $1,168.00 to $1,163.00 and set a “buy” rating on the stock in a report on Monday, March 30th. Morgan Stanley reaffirmed an “overweight” rating and set a $1,313.00 price objective on shares of Eli Lilly and Company in a report on Thursday, March 5th. Finally, Royal Bank Of Canada assumed coverage on shares of Eli Lilly and Company in a report on Tuesday, February 24th. They set an “outperform” rating and a $1,250.00 price objective on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $1,222.22.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $952.24 on Thursday. The company’s fifty day moving average price is $987.31 and its 200-day moving average price is $973.10. The firm has a market capitalization of $899.69 billion, a price-to-earnings ratio of 41.49, a PEG ratio of 1.09 and a beta of 0.51. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,133.95. The company has a debt-to-equity ratio of 1.54, a current ratio of 1.58 and a quick ratio of 1.19.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, topping analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The firm had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. During the same quarter in the prior year, the firm earned $5.32 EPS. The business’s revenue for the quarter was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, equities research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: FDA approval and commercial setup: Lilly secured approval for its oral weight‑loss drug Foundayo and management says production is ready to scale, supporting near‑term revenue upside from obesity treatments. Great News for Eli Lilly Stock Investors!
• Positive Sentiment: Buy arguments and analyst support: multiple bullish writeups (including a “3 Reasons To Buy” piece and a modest price‑target raise after approval) highlight durable cash flows from GLP‑1 drugs and refreshed upside assumptions. 3 Reasons To Buy Eli Lilly Now Price Target Raised After FDA Approval
• Positive Sentiment: Pipeline diversification: Lilly amended its collaboration with AC Immune to advance next‑generation tau inhibitors toward IND‑enabling studies in 2026, expanding long‑term Alzheimer’s/neurodegeneration exposure beyond metabolic drugs. Eli Lilly Extends AC Immune Tau Pact
• Neutral Sentiment: Investor attention and commentary: Zacks and other outlets note heavy investor interest and that Lilly has lagged recent market gains despite its headline activity — useful context for short‑term volume/volatility. Eli Lilly (LLY) Ascends But Remains Behind Market
• Negative Sentiment: Competitive pricing pressure: Novo Nordisk launched a higher‑dose Wegovy at a significantly lower cash price than Lilly’s Zepbound/Foundayo positioning, creating margin and market‑share risks in the obesity market. Novo Nordisk Unveils $399 Wegovy HD
• Negative Sentiment: Analyst downgrade / short‑term sell pressure: reports show at least one analyst downgrade that pushed intraday selling and headlines about the stock dipping after the new approval, reflecting investor sensitivity to competition and side‑effect narratives. Trading Down on Analyst Downgrade Stock Dips Following FDA Approval
• Negative Sentiment: Valuation/forecast adjustments: at least one research note trimmed fair‑value assumptions slightly while leaving a high base case, underscoring debates over how much obesity/diabetes upside is already priced in. Obesity & Diabetes Story Reframes Investment Narrative

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.